Peritoneal Cancer
139
19
31
72
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
38 trials with published results (27%)
Research Maturity
72 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.1%
14 terminated out of 139 trials
83.7%
-2.8% vs benchmark
11%
15 trials in Phase 3/4
53%
38 of 72 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 72 completed trials
Clinical Trials (139)
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Using Aspirin to Improve Immunological Features of Ovarian Tumors
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases
The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study.
Depression Treatment and Screening in Ovarian Cancer Patients
Choices About Genetic Testing And Learning Your Risk With Smart Technology
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Genomic BRCA and Extensive ovArian Cancer Testing
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
Nudge to Gynecologic Oncology
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer